慢性乙型病毒性肝炎患者血清IL-33和sST2表达水平及临床诊治意义

郑绍同; 王书中; 杨士军; 潘峰; 付启云

doi:10.3969/j.issn.1671-038X.2017.09.06

慢性乙型病毒性肝炎患者血清IL-33和sST2表达水平及临床诊治意义

- 1. 南京医科大学附属淮安第一医院医学检验中心, 江苏淮安 223300;
- 2. 南京医科大学附属淮安第一医院消化科, 江苏淮安 223300

详细信息

作者简介:
郑绍同,男,本科,主任检验师。研究方向:临床免疫学

通讯作者: 付启云,E-mail:fuqy1969@163.com

中图分类号: R575.1

收稿日期: 2017-04-15

Expression and clinical significance of serum IL-33 and sST2 in patients with chronic hepatitis B

- 1. Department of Clinical laboratory, Huai'an First People's Hospital, Nanjing Medical University, Jiangsu Huaian 223300, China;
- 2. Department of Gastroenterology, the First Affiliated Hospitalof Nanjing Medical University, Jiangsu Huaian 223300, China

More Information

Corresponding author: FU Qi-yun, E-mail: fuqy1969@163.com

Received Date: 15 April 2017

摘要

摘要: [目的]通过分析慢性乙肝患者血清中IL-33和sST2的表达情况及其与患者AST的相关性,探讨其在患者预后中的预测价值。[方法]选取2015年10月~2016年12月我院收治的慢性HBV患者100例及同时期门诊健康体检者30例纳入研究对象,收集慢性乙肝患者的临床资料,检测血清IL-33、sST2、AST的浓度,分析IL-33、sST2与AST之间的关系。[结果]100例慢性乙肝患者作为实验组分为AST1~3 ULN、AST＞3~5 ULN、AST＞5~8 ULN、AST＞8 ULN4组。对照组患者血清IL-33和sST2浓度分别为(15.32±5.61)pg/ml、(0.11±0.04)μg/ml,与AST1~3 ULN组血清IL-33浓度(12.63±7.38)pg/ml及sST2浓度(0.09±0.03)μg/ml比较差异均无统计学意义(P＞0.05);但其均显著低于AST＞3~5 ULN组IL-33浓度(31.27±18.33)pg/ml及sST2浓度(0.34±0.11)μg/ml、AST＞5~8 ULN组IL-33浓度(66.81±28.62)pg/ml及sST2浓度(0.98±0.33)μg/ml、AST＞8 ULN组IL-33浓度(155.79±51.27)pg/ml及sST2浓度(3.88±1.69)μg/ml,差异均有统计学意义(P＜0.01);对照组患者血清AST浓度(17.16±4.89)U/L均显著低于实验组各分组,差异均有统计学差异(P＜0.01)。慢性乙肝患者血清IL-33、sST2水平与AST水平呈正相关(r_IL-33, _AST=0.572,r_sST2,AST=0.451,P＜0.05);所有研究对象血清IL-33、sST2水平与AST水平也呈正相关(r_IL-33, _AST=0.469,r_sST2,AST=0.433,P＜0.05)。[结论]IL-33、sST2某种条件下可反映肝脏的炎症程度,可作为慢性乙型病毒性肝炎肝脏损伤的标志之一,可以指导患者抗病毒治疗方法的选择并用以评价其治疗效果。
- 慢性乙型病毒性肝炎 /
- IL-33 /
- sST2 /
- 表达水平 /
- 临床意义
Abstract: [Objective]To investigate the predictive value in the prognosis of patients with chronic hepatitis B by analyzing the serum expressions of IL-33 and sST2 and its correlation with the AST levels.[Methods]100 cases with chronic HBV and 30 healthy subjects at the same time from October 2015 to December 2016 year in our hospital outpatient service were enrolled in the study.The clinical data of patients with chronic hepatitis B were collected.To detect the relationship between the serum IL-33,sST2,AST,and to analyze the relationship between IL-33,sST2 and AST.[Results]100 cases of chronic hepatitis B patients as the experimental group were divided into AST1~ 3 ULN,AST＞3~5 ULN,AST＞5~8 ULN,AST＞8 ULN four groups.The serum IL-33 and sST2 concentrations of control group were(15.32±5.61)pg/ml and(0.11±0.04)g/ml,and those were no statistically significant difference with AST1~ 3 ULN group serum IL-33 concentration(12.63±7.38)pg/ml and the concentration of sST2(0.09±0.03)g/ml(P>0.05).The serum IL-33 and sST2 concentrations of control group were significantly lower than those in the AST＞3~5 ULN group[IL-33(31.27±18.33)pg/ml and sST2(0.34±0.11)g/ml]and AST＞5~8 ULN group[IL-33(66.81±28.62)pg/ml and sST2(0.98±0.33)g/ml]and AST＞8 ULN group[IL-33(155.79±51.27)pg/ml and sST2(3.88±1.69)g/ml],there were all statistically significant difference(P<0.01).The serum concentration of AST in the control group(17.16±4.89)U/L were significantly lower than that in the all experimental group,there were statistically significant difference(P<0.01).There were positive relationship betwee serum IL-33,sST2 level and AST level in Chronic hepatitis B patients(r_IL-33,AST=0.572,r_sST2,AST=0.451,P<0.05).The serum IL-33,sST2 level and AST level were positively correlated in all subjects(r_IL-33,AST=0.469,r_sST2,AST=0.433,P<0.05).[Conclusion]The levels of IL-33 and sST2 can reflect the degree of liver inflammation under some conditions,which can be used as one of the signs of liver injury in chronic hepatitis B and the selection of antiviral treatment methods can be directed to evaluate the effectiveness of the treatment.
- chronic hepatitis B /
- IL-33 /
- sST2 /
- expression level /
- significance

HTML全文

参考文献(26)

[1]	中华医学会肝病学分会.慢性乙型肝炎防治指南 (2015年版)[J].实用肝脏病杂志, 2016, 19 (3):389-400.
[2]	Roushan M R, Mohammadpour M, Baiany M, et al.Time to seroconversion of HBsAg to anti-HBs in individuals who lost HBsAg during follow-up[J].Epidemiology&Infection, 2016, 144 (12):2648-2653.
[3]	Carvalhana S C, Leit2o J, Alves A C, et al.Hepatitis B and C prevalence in Portugal:disparity between the general population and high-risk groups[J].Eur Gastroenterol Hepatol, 2016, 28 (6):640-640.
[4]	乔兵, 孙学华, 张鑫, 等.CCR5在慢性乙型肝炎中的研究进展[J].中国免疫学杂志, 2015, 31 (9):1269-1273.
[5]	赵霞, 盛慧萍, 杨岩, 等.慢性乙型肝炎患者外周血IL-17细胞因子水平及其临床意义[J].西安交通大学学报:医学版, 2017, 38 (1):83-87.
[6]	Zhao P W, Shi X, Li C, et al.IL-33EnhancesHumoral Immunity Against Chronic HBV Infection Through Activating CD4 (+) CXCR5 (+) TFH Cells[J].J Interferon Cytokine Res, 2015, 35 (6):454-454.
[7]	Reichenbach D K, Schwarze V, Matta B M, et al.The IL-33/ST2 axis augments effector T-cell responses during acute GVHD[J].Blood, 2015, 125 (20):3183.
[8]	王红霞, 彭粉花.IL-33和ST2在慢加急性乙型肝炎肝衰竭和慢性乙型肝炎患者中水平差异及应用研究[J].检验医学与临床, 2016, 13 (23):3339-3341.
[9]	中华医学会肝病学分会.慢性乙型肝炎防治指南 (2015年版)[J].实用肝脏病杂志, 2016, 19 (3):389-400.
[10]	王晓琳, 邹桂舟, 叶珺, 等.乙肝表面抗原在慢性乙型肝炎病毒感染临床不同阶段的变化[J].实用医学杂志, 2014, 30 (17):2765-2767.
[11]	宋为娟, 谢而付, 赵中建, 等.慢性HBV患者HBeAg血清学转换过程中肝损伤指标比较[J].实用医学杂志, 2016, 32 (9):1518-1520.
[12]	乔艳, 徐东平, 李进.慢性乙型肝炎的免疫治疗研究进展[J].实用肝脏病杂志, 2016, 19 (4):493-496.
[13]	王燕, 杨德平, 汤明荣.肝脏相关疾病患者ALT和HBV DNA定量检测结果分析[J].中国医师杂志, 2016, 18 (s1):128-130.
[14]	常凤霞, 郝娟, 朋毛措, 等.慢性乙型肝炎患者HBVDNA与Th1/Th2相关性分析[J].海南医学院学报, 2016, 22 (15):1649-1652.
[15]	张坤坤, 袁吉钊.Ⅰ型固有淋巴细胞对慢性乙型肝炎的作用及机制[J].免疫学杂志, 2016, 31 (2):145-151.
[16]	Mertz K D, Mager L F, Wasmer M H, et al.The IL-33/ST2pathway contributes to intestinal tumorigenesis in humans and mice[J].Oncoimmunology, 2016, 5 (1):1-11.
[17]	李华, 张素贞, 贾倩, 等.慢性乙型肝炎患者白细胞介素33水平变化研究[J].医学综述, 2015, 21 (11):2081-2083.
[18]	Gao X, Wang X, Yang Q, et al.Tumoral expression of IL-33inhibits tumor growth and modifies the tumor microenvironment through CD8+T and NK cells[J].J Immunol, 2015, 194 (1):438-445.
[19]	姜绍文, 林兰意, 项晓刚, 等.IL-33及其受体ST2在D-GalN/LPS诱导的急性肝功能衰竭小鼠中的表达及意义[J].肝脏, 2016, 21 (4):267-272.
[20]	Gao S, Huan S L, Han L Y, et al.Overexpression of serum sST2is associated with poor prognosis in acuteon-chronic hepatitis B liver failure[J].Clin Res Hepatol Gastroenterol, 2014, 39 (3):315-323.
[21]	Tirado-Sánchez A, Bonifaz A, Ponce-Olivera R M.Elevated IL-33and sST2levels in sera of patients with pemphigus vulgaris.Correlation with clinical and immunological parameters during follow up[J].Br J Dermatol, 2015, 173 (3):818-20.
[22]	斯琴, 关英慧, 唐颖, 等.IL-33和sST2在恶性胸腔积液和结核性胸腔积液患者胸腔积液和外周血中的表达水平及其临床意义[J].吉林大学学报:医学版, 2017, 43 (1):91-95.
[23]	高巧艳, 李明才, 李燕, 等.IL-33/ST2信号通路在纤维化疾病中的作用[J].中国病理生理杂志, 2013, 29 (9):1712-1717.
[24]	Vocca L, Sano C D, Uasuf C G, et al.IL-33/ST2axis controls Th2/IL-31and Th17immune response in allergic airway diseases[J].Immunobiology, 2015, 220 (8):954-954.
[25]	Blom L, Poulsen LK.IL-1flamily members IL-18and IL-33upregulate the inflammatory potential of differentiated human Th1and Th2cultures[J].J Immunol, 2012, 189 (9):4331-4337.
[26]	Rechardt M, Shiri R, Matikainen S, et al.Soluble IL-1RII and IL-18are associated with incipient upper extremity soft tissue disorders[J].Cytokine, 2011, 54 (2):149-153.